Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to control brain tumors in lung cancer patients

NCT ID NCT07505173

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Apr 08, 2026 · Last updated Jun 16, 2026 · Updated 11 times

Summary

This study tests a new treatment for people with a specific type of lung cancer (EGFR-mutated) that has spread to the brain and causes symptoms. It combines whole-brain radiation (with protection for memory areas) and a daily targeted pill called osimertinib. The goal is to see if this approach can better control brain tumors while preserving quality of life. About 74 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAIVE ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR-SENSITIVE MUTATIONS (EGFR EXON 19 DELETION AND EXON 21 L858R MUTATION) AND SYMPTOMATIC BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tianjin Medical University Cancer Institute and Hospital

    RECRUITING

    Tianjin, China

Conditions

Explore the condition pages connected to this study.

NAIVE ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR-SENSITIVE MUTATIONS (EGFR EXON 19 DELETION AND EXON 21 L858R MUTATION) AND SYMPTOMATIC BRAIN METASTASES